Nonalcoholic Steatohepatitis Completed Phase 2 Trials for Fluorescein lisicol (DB12030)

IndicationStatusPhase
DBCOND0029353 (Nonalcoholic Steatohepatitis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00794716Pharmacokinetics of NRL972 in Patients With Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)Diagnostic